
Insulet (PODD) Stock Forecast & Price Target
Insulet (PODD) Analyst Ratings
Bulls say
Insulet is a strong investment opportunity due to its leadership position in the growing automated insulin delivery market, its solid financial performance with plans for continued growth and profitability, and its commitment to innovation through ongoing R&D investments. While there are some challenges, such as potential supply chain disruptions and competition in the market, Insulet's differentiated product and global reach position it well for long-term success. With potential upside risks from faster adoption and execution in key areas, and a fair valuation based on EV/Sales and EV/EBITDA multiples, a positive outlook on this stock is supported.
Bears say
Insulet is facing a number of headwinds, including market risks and global inflationary trends, competition from other companies in the diabetes market, potential intellectual property challenges and patent litigation, and shifts in government regulations and reimbursement policies. In addition, the company's recent downward revision in its sales outlook has raised concerns about its ability to maintain growth and profitability in the future. These factors, coupled with uncertainty surrounding management's plans and potential competition in the patch pump market, warrant a negative outlook for Insulet's stock.
This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.
Insulet (PODD) Analyst Forecast & Price Prediction
Start investing in Insulet (PODD)
Order type
Buy in
Order amount
Est. shares
0 shares